Effects of Tongxinluo Capsules combined with enhanced external counterpulsation on dual-heart treatment and cognitive function in patients with ischemic cardiomyopathy heart failure
ZHANG Aiai
LI Feixing
LI Huixian
Abstract：Objective To investigate the effects of Tongxinluo Capsules combined with enhanced external counterpulsation(EECP)on dual-heart treatment outcomes and cognitive function in patients with ischemic cardiomyopathy(ICM)with heart failure.Methods Select 236 patients diagnosed with ICM heart failure who were hospitalized from February 2022 to June 2024.Randomly divide them into the control group and the experimental group,with 118 cases in each group.All patients received conventional heart failure pharmacotherapy.Patients in the control group additionally underwent EECP,while those in the experimental group received both EECP and Tongxinluo Capsules(4 capsules,3 times daily).EECP was administered 5 times weekly(60 minutes/session).Before and after 35 weeks of treatment,the 6-minute walking distance(6MWD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),anxiety(Self-Rating Anxiety Scale[SAS]),depression(Self-Rating Depression Scale[SDS]),sleep quality(the Pittsburgh Sleep Quality Index[PSQI]),and cognition(Mini-Mental State Examination[MMSE],Montreal Cognitive Assessment[MoCA])were compared.Fasting venous blood samples were analyzed for triglycerides(TG),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),aspartate aminotransferase(AST),alanine aminotransferase(ALT),creatinine(Cr),and brain natriuretic peptide(BNP)via immunoassay.Results Baseline 6 MWD,LVEF,LVEDD,BNP,MoCA,MMSE,SAS,SDS,PSQI,TC,TG,HDL-C,LDL-C,ALT,AST,and Cr showed no significant differences between groups(P>0.05).After 35 weeks,both groups exhibited significantly increased 6MWD,LVEF,MoCA,and MMSE scores(P<0.05),and reduced BNP,LVEDD,SAS,SDS,and PSQI scores(P<0.05).The experimental group demonstrated superior improvements in the 6MWD,LVEF,MoCA,and MMSE(P<0.05),with significantly lower BNP,LVEDD,SAS,SDS,and PSQI scores compared to the control group(P<0.05).Conclusion Tongxinluo Capsules combined with EECP improves dual-heart treatment outcomes and cognitive function in ICM with heart failure patients,suggesting a novel therapeutic approach for this population.
Keywords：ischemic cardiomyopathy with heart failureenhanced external counterpulsationTongxinluo Capsuledual-heart treatmentcognitive function
Publication Date：2026-02-26
Online Publishing Date：2026-03-23(First online date of this platform, not the publication date of the document)
Pages：5( 223-226,231 )